BRAF and MEK inhibitors have been developed as a breakthrough treatment for BRAF mutant melanoma patients; however, the development of resistance after a median progression-free survival of just over 12 months in patients with advanced disease remains a clinical challenge [4,5]. This evidence concerns the gene BRAF and melanoma.